Literature DB >> 7784562

Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.

H Minn1, K R Zasadny, L E Quint, R L Wahl.   

Abstract

PURPOSE: To study the precision of repeated 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) uptake measurements at positron emission tomography (PET) in patients with primary lung cancer.
MATERIALS AND METHODS: Ten patients with untreated lung cancer underwent two dynamic FDG PET examinations after a 4-hour fast within 1 week. Kinetic modeling of tumor FDG uptake was performed on the basis of a three-compartment model. The tumor concentration of F-18 (standardized uptake value calculated on the basis of predicted lean body mass [SUV-lean]) was also measured 50-60 minutes after injection of a tracer. Blood glucose, insulin, and free fatty acid levels were monitored.
RESULTS: SUV-lean and the FDG influx constant Ki were measured with a mean +/- standard deviation difference of 10% +/- 7 and 10% +/- 8, respectively, over repeated PET scans. The mean difference was reduced to 6% +/- 6 and 6% +/- 5 by multiplying SUV-lean and Ki by plasma glucose concentration.
CONCLUSION: SUV-lean and graphical Ki can be measured reproducibly, supporting their use in quantitative FDG PET algorithms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784562     DOI: 10.1148/radiology.196.1.7784562

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  77 in total

1.  Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.

Authors:  R K Doot; J S Scheuermann; P E Christian; J S Karp; P E Kinahan
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

2.  Metrology Standards for Quantitative Imaging Biomarkers.

Authors:  Daniel C Sullivan; Nancy A Obuchowski; Larry G Kessler; David L Raunig; Constantine Gatsonis; Erich P Huang; Marina Kondratovich; Lisa M McShane; Anthony P Reeves; Daniel P Barboriak; Alexander R Guimaraes; Richard L Wahl
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

3.  Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Savannah C Partridge; Risa K Vanantwerp; Robert K Doot; Xiaoyu Chai; Brenda F Kurland; Peter R Eby; Jennifer M Specht; Lisa K Dunnwald; Erin K Schubert; Constance D Lehman; David A Mankoff
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

4.  Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.

Authors:  Nanda C Krak; R Boellaard; Otto S Hoekstra; Jos W R Twisk; Corneline J Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-15       Impact factor: 9.236

Review 5.  FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard L Wahl
Journal:  Curr Opin Oncol       Date:  2008-03       Impact factor: 3.645

6.  Quantitative Imaging Biomarkers Alliance FDG-PET/CT Working Group report.

Authors:  Richard Frank
Journal:  Mol Imaging Biol       Date:  2008 Nov-Dec       Impact factor: 3.488

7.  Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Authors:  Wolfgang A Weber; Constantine A Gatsonis; P David Mozley; Lucy G Hanna; Anthony F Shields; Denise R Aberle; Ramaswamy Govindan; Drew A Torigian; Joel S Karp; Jian Q Michael Yu; Rathan M Subramaniam; Robert A Halvorsen; Barry A Siegel
Journal:  J Nucl Med       Date:  2015-04-23       Impact factor: 10.057

8.  A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Authors:  Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

9.  Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

Authors:  Yusuf Menda; Laura L Boles Ponto; Michael K Schultz; Gideon K D Zamba; G Leonard Watkins; David L Bushnell; Mark T Madsen; John J Sunderland; Michael M Graham; Thomas M O'Dorisio; M Sue O'Dorisio
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

10.  PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.

Authors:  Paul E Kinahan; Robert K Doot; Michelle Wanner-Roybal; Luc M Bidaut; Samuel G Armato; Charles R Meyer; Geoffrey McLennan
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.